SCHEMBL130590

SCHEMBL130590

COc1cccc(-c2nn(C)c3ncnc(N)c23)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 16/20 0.73
ABL1 P00519 14/20 0.73
EGFR P00533 12/20 0.73
PIK3CD O00329 10/20 0.73
PIK3CA P42336 10/20 0.73
PIK3CB P42338 10/20 0.73
PIK3CG P48736 10/20 0.73
PRKDC P78527 10/20 0.73
HCK P08631 9/20 0.73
MTOR P42345 8/20 0.73
EPHB4 P54760 8/20 0.73
KDR P35968 7/20 0.73
PI4KB Q9UBF8 3/20 0.73
NUDT14 O95848 1/20 0.65
NUDT5 Q9UKK9 1/20 0.65
RIPK1 Q13546 1/20 0.58
ABL2 P42684 3/20 0.56
CDK1 P06493 1/20 0.56
LCK P06239 1/20 0.55
EPHA3 P29320 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL129870 0.88 SRC (0.77) SRCABL1EGFRPIK3CDPIK3CA
SCHEMBL129505 0.87 PIK3CD (0.62) SRCABL1EGFRPIK3CDPIK3CA
SCHEMBL128513 0.87 PIK3CD (0.67) SRCABL1EGFRPIK3CDPIK3CA
SCHEMBL129615 0.86 SRC (0.79) SRCABL1EGFRPIK3CDPIK3CA
SCHEMBL197491 0.86 PIK3CD (0.65) SRCABL1EGFRPIK3CDPIK3CA
SCHEMBL130468 0.86 PIK3CD (0.65) SRCABL1EGFRPIK3CDPIK3CA
SCHEMBL17970673 0.86 PIK3CD (0.65) SRCABL1EGFRPIK3CDPIK3CA
SCHEMBL2467650 0.84 SRC (1.00) SRCABL1EGFRPIK3CDPIK3CA
SCHEMBL130421 0.84 PIK3CD (0.78) SRCABL1EGFRPIK3CDPIK3CA
SCHEMBL130752 0.84 NUDT14 (0.74) SRCABL1EGFRPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2021-12-30 US disclosed
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2021-06-01 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-09-19 US disclosed
US-10322130-B2 Substituted chromenones as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-06-18 US disclosed
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-04-11 US disclosed
US-10220035-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-03-05 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
WO-2012151525-A9 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-12-13 WO disclosed
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-15 US disclosed
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-15 US disclosed
WO-2012151525-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-08 WO disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 SRC 202/4885ABL1 329/4885EGFR 929/4885
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB SRC 285/4885ABL1 334/4885EGFR 1359/4885
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases MAP4K2, MAP3K20, MAP3K1 SRC 85/4885ABL1 106/4885EGFR 520/4885
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB SRC 285/4885ABL1 334/4885EGFR 1359/4885
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKAR2B SRC 254/4885ABL1 464/4885EGFR 1502/4885
US-10220035-B2 Compounds as modulators of protein kinases PRKCA, PRKCH, PRKCE SRC 205/4885ABL1 297/4885EGFR 1203/4885
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB SRC 285/4885ABL1 334/4885EGFR 1359/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885ABL1 465/4885EGFR 1667/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885ABL1 465/4885EGFR 1667/4885
US-10322130-B2 Substituted chromenones as modulators of protein kinases MAP3K1, CSNK1A1, MAP3K2 SRC 90/4885ABL1 376/4885EGFR 807/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A SRC 110/4885ABL1 258/4885EGFR 510/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885ABL1 465/4885EGFR 1667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.